Role of capsule endoscopy in alarm features and non-responsive celiac disease: A European multicenter study
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perez-Cuadrado-Robles, E
- Lujan-Sanchis, M
- Elli, L
- Juanmartiñena-Fernández JF
- Garcia-Lledo, J
- Ruano-Diaz, L
- Egea-Valenzuela, J
- Jimenez-Garcia, VA
- Arguelles-Arias, F
- Sanjuan-Acosta M
- Carretero-Ribon, C
- Rosa, B
- Sanchez-Ceballos, F
- Lopez-Higueras, A
- Fernandez-Urien-Sainz, I
- Branchi, F
- Valle-Munoz, J
- Borque-Barrera, P
- Gonzalez-Vazquez, S
- Xavier, S
- Gonzalez-Suarez, B
- Herrerias-Gutierrez, JM
- Perez-Cuadrado-Martinez, E
- Sempere-Garcia-Arguelles, J
- Enteroscopy and Capsule Endoscopic Spanish Society Group of the Spanish Society
Grupos
Abstract
Background and AimThe role of capsule endoscopy (CE) in established celiac disease (CD) remains unclear. Our objective was to analyze the usefulness of CE in the suspicion of complicated CD. MethodsThis was a retrospective multicenter study. One hundred and eighty-nine celiac patients (mean age: 46.616.6, 30.2% males) who underwent CE for alarm symptoms (n=86, 45.5%) or non-responsive CD (n=103, 54.5%) were included. Diagnostic yield (DY), therapeutic impact and safety were analyzed. ResultsCapsule endoscopy was completed in 95.2% of patients (small bowel transit time: 270.5100.2min). Global DY was 67.2%, detecting atrophic mucosa (n=92, 48.7%), ulcerative jejunoileitis (n=21, 11.1%), intestinal lymphoma (n=7, 3.7%) and other enteropathies (n=7, 3.7%, six Crohn's disease cases and one neuroendocrine tumor). The DY of CE was significantly higher in patients presenting with non-responsive disease compared to patients with alarm symptoms (73.8% vs 59.3%, P=0.035). The new findings of the CE modified management in 59.3% of the cases. There were no major complications. ConclusionCapsule endoscopy may be a moderately helpful and safe diagnostic tool in the suspicion of complicated CD, modifying the clinical course of these patients.
Datos de la publicación
- ISSN/ISSNe:
- 0915-5635, 1443-1661
- Tipo:
- Article
- Páginas:
- 461-466
- DOI:
- 10.1111/den.13002
- PubMed:
- 29253321
- Factor de Impacto:
- 1,363 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
DIGESTIVE ENDOSCOPY WILEY
Citas Recibidas en Web of Science: 18
Documentos
- No hay documentos
Filiaciones
Keywords
- capsule endoscopy; celiac disease; gluten; lymphoma; non-responsive celiac disease
Proyectos y Estudios Clínicos
RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010
WIBEC. WIRELESS IN-BODY ENVIRONMENT COMMUNICATIONS.
Investigador Principal: VICENTE PONS BELTRÁN
675353 . COMISION EUROPEA . 2016
ESTUDIO DE FASE III, ALEATORIZADO, A DOBLE CIEGO, CONTROLADO CON PLACEBO SOBRE TERAPIA ADYUVANTE CON VEMURAFENIB (RO5185426) EN PACIENTES CON MELANOMA CUTÁNEO CON MUTACIÓN DE BRAF RESECADO QUIRÚRGICAMENTE CON ALTO RIESGO DE RECIDIVA.
Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE
GO27826 . 2013
ESTUDIO ALEATORIZADO Y ABIERTO, PARA COMPARAR DURANTE 26 SEMANAS EL EFECTO DEL TRATAMIENTO CON GEL INTESTINAL DE LEVODOPA-CARBIDOPA (GILC) Y DEL TRATAMIENTO MÉDICO ÓPTIMO (TMO) SOBRE LOS SÍNTOMAS NO MOTORES (SNM) EN PACIENTES CON ENFERMEDAD DE PARKINSON AVANZADA - ESTUDIO INSIGHTS.
Investigador Principal: IRENE MARTÍNEZ TORRES
M12-927 . 2015
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF CHRONIC POUCHITIS./ ESTUDIO DE FASE IV ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE ENTYVIO (VEDOLIZUMAB I.V.) EN EL TRATAMIENTO DE LA POUCHITIS CRÓNICA.
Investigador Principal: GUILLERMO BASTIDA PAZ
VEDOLIZUMAB-4004 . 2017
IMPACTO DE LA PAPILOTOMIA DURANTE LA COLANGIOPANCREATOGRAFÍA RETRÓGRADA ENDOSCÓPICA (CPRE) PARA LA IMPLANTACION DE UN STENT BILIAR METALICO NO CUBIERTOEN PACIENTES CON ICTERICIA OBSTRUCTIVA POR TUMORES MALIGNOS DE PANCREAS
Investigador Principal: VICENTE PONS BELTRÁN
PAP-ADE-01
ESTUDIO ALEATORIZADO, ENMASCARADO, CONTROLADO CON PLACEBO SOBRE LOS EFECTOS DE ADALIMUMAB INTRALESIONAL EN ESTENOSIS INTESTINALES DE PACIENTES CON ENFERMEDAD DE CROHN.
Investigador Principal: LIDIA ARGÜELLO VIUDEZ
CSAI
ENSAYO FASE 2A PARA EVALUAR LA EFICACIA Y SEGURIDAD DE MEDI2070 EN PACIENTES CON ENFERMEDAD DE CROHN MODERADA A GRAVE QUE NO HAN RESPONDIDO O NO TOLERAN LA TERAPIA CON ANTIFACTOR DE NECROSIS TUMORAL ALFA.
Investigador Principal: GUILLERMO BASTIDA PAZ
CD-IA-MEDI2070-1147/D5170C00001
Cita
Perez E,Lujan M,Elli L,Juanmartiñena JF,Garcia J,Ruano L,Egea J,Jimenez VA,Arguelles F,Sanjuan M,Carretero C,ALONSO N,Rosa B,Sanchez F,Lopez A,Fernandez I,Branchi F,Valle J,Borque P,Gonzalez S,PONS V,Xavier S,Gonzalez B,Herrerias JM,Perez E,Sempere J,Enteroscopy and Capsule Endoscopic Spanish Group of the Spanish S. Role of capsule endoscopy in alarm features and non-responsive celiac disease: A European multicenter study. Dig. Endosc. 2018. 30. (4):p. 461-466. IF:3,640. (1).